The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.
Nick van EsMatthew VentrescaMarcello Di NisioQi ZhouSimon NobleMark CrowtherMatthias BrielDavid GarciaGary H LymanFergus MacbethGareth GriffithsAlfonso IorioLawrence MbuagbawIgnacio NeumannJan BrozekGordon GuyattMichael B StreiffTejan BaldehIvan D FlorezOzlem Gurunlu AlmaGiancarlo AgnelliWalter AgenoMaura MarcucciGeorge BozasGilbert ZulianAnthony MaraveyasBernard LebeauRamon LecumberriKostandinos SiderasCharles LoprinziRobert McBaneUwe PelzerHanno RiessZiad SolhJames PerryLara A KahalePatrick M BossuytClara KlerkHarry R BüllerElie A AklHolger J Schünemannnull nullPublished in: Journal of thrombosis and haemostasis : JTH (2020)
The Khorana score was unable to stratify patients with lung cancer based on their VTE risk. Among those with other cancer types, a high-risk score was associated with a three-fold increased risk of VTE compared with a low-to-intermediate risk score. Thromboprophylaxis was effective and safe in patients with a high-risk Khorana score.